- Home
- PBYI vs TVRD Comparison
PBYI vs TVRD Comparison
Compare PBYI & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PBYI | TVRD |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 246.5M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | TVRD |
|---|---|---|
| Price | $5.27 | $4.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $7.00 | ★ $51.67 |
| AVG Volume (30 Days) | ★ 637.1K | 137.0K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.87 | N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $211,995,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.10 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.58 | $3.74 |
| 52 Week High | $6.12 | $43.65 |
Technical Indicators
Market Signals| Indicator | PBYI | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 55.90 | 29.49 |
| Support Level | $4.84 | $3.74 |
| Resistance Level | $5.11 | $4.18 |
| Average True Range (ATR) | 0.19 | 0.27 |
| MACD | 0.04 | 0.69 |
| Stochastic Oscillator | 91.59 | 69.70 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.